enVVeno Medical financials
$8.63−2.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$20.9M | -$23.8M | -$25.2M | -$24.9M | -$16.9M |
| Net income | -$19.5M | -$21.8M | -$23.5M | -$24.7M | -$16.5M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-33.06 | $-44.53 | $-66.85 | $-77.00 | $-66.50 |
| EBITDA | -$20.8M | -$23.6M | -$25.0M | -$24.4M | -$16.7M |
| Operating cash flow | -$15.6M | -$16.8M | -$18.9M | -$15.6M | -$11.8M |
| Free cash flow | -$15.6M | -$16.9M | -$18.9M | -$15.7M | -$12.2M |
| Diluted shares | 0.6M | 0.5M | 0.4M | 0.3M | 0.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $3.1M | $1.8M | $3.6M | $4.6M | $54.7M |
| Short-term investments | $25.1M | $41.4M | $42.8M | $34.5M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $29.6M | $45.0M | $48.6M | $41.7M | $57.7M |
| Total liabilities | $2.4M | $2.8M | $2.4M | $2.9M | $3.3M |
| Shareholders' equity | $27.1M | $42.2M | $46.2M | $38.7M | $54.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology